Literature DB >> 29367298

Evaluation of Non-Tissue Culture- versus Tissue Culture-Treated Microplates for Oritavancin Susceptibility Testing.

Qun Yan1,2, Melissa J Karau1, Robin Patel3,4.   

Abstract

Entities:  

Keywords:  broth microdilution susceptibility testing; non-tissue culture treated; oritavancin; polysorbate 80; tissue culture treated

Mesh：

Substances：

Year:  2018        PMID： 29367298      PMCID： PMC5869813          DOI： 10.1128/JCM.02001-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  10 in total

1.  Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Authors:  Robert P Rennie; Laura Koeth; Ronald N Jones; Thomas R Fritsche; Cindy C Knapp; Scott B Killian; Beth P Goldstein
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

2.  Colistin susceptibility testing: time for a review.

Authors:  Mahableshwar Albur; Alan Noel; Karen Bowker; Alasdair Macgowan
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790

3.  EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-10       Impact factor: 8.067

4.  Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci.

Authors:  Francis F Arhin; Gregory Moeck
Journal:  J Glob Antimicrob Resist       Date:  2017-04-25       Impact factor: 4.035

5.  In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections.

Authors:  Javier Fernández; Kerryl E Greenwood-Quaintance; Robin Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2016-05-13       Impact factor: 2.803

6.  Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.

Authors:  Ronald N Jones; Greg Moeck; Francis F Arhin; Michael N Dudley; Paul R Rhomberg; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

7.  Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions.

Authors:  Matti Karvanen; Christer Malmberg; Pernilla Lagerbäck; Lena E Friberg; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

8.  Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Authors:  Francis F Arhin; Ingrid Sarmiento; Adam Belley; Geoffrey A McKay; Deborah C Draghi; Parveen Grover; Daniel F Sahm; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

9.  Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters.

Authors:  Francis F Arhin; Karla Tomfohrde; Deborah C Draghi; Mohana Aranza; Thomas R Parr; Daniel F Sahm; Gregory Moeck
Journal:  Diagn Microbiol Infect Dis       Date:  2008-07-09       Impact factor: 2.803

10.  Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.

Authors:  Katharina Neudorfer; Suzannah M Schmidt-Malan; Robin Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2017-09-27       Impact factor: 2.803
  10 in total
  2 in total

1.  Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.

Authors:  Qun Yan; Melissa J Karau; Yash S Raval; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

2.  In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient.

Authors:  Eric Wenzler; Maressa Santarossa; Kevin A Meyer; Amanda T Harrington; Gail E Reid; Nina M Clark; Fritzie S Albarillo; Zackery P Bulman
Journal:  Open Forum Infect Dis       Date:  2020-01-04       Impact factor: 3.835
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.